Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
Exact Sciences (EXAS +9.6%) is up on average volume in apparent response to data from colorectal cancer (CRC) biopsy samples generated by privately held Fr
Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.
DUBLIN--(BUSINESS WIRE)--The "2020 Global Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies" report has been added to ResearchAnd
DUBLIN--(BUSINESS WIRE)--The "2020 U.K. Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies" report has been added to ResearchAndMa
Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.
MADISON, Wis., Jan. 2, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following investor conference and invited investors to p
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE